SOL-257
/ SOLA Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 23, 2024
Novel chaperone-based gene therapy for ALS
(Neuroscience 2024)
- "This in vivo proof of concept study demonstrated that SOL-257 gene therapy effectively prevents TDP-43-related toxicity in a mouse model of ALS. These results strongly support the continued preclinical development of SOL-257 for ALS treatment. Moreover, the adaptability of this gene therapy platform, which expresses engineered co-chaperones with tailored target specificities, holds promise for treating a range of protein misfolding diseases."
Gene therapy • CNS Disorders • Proteinopathy • TARDBP
November 10, 2023
SOLA Biosciences Presents Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS, at Neuroscience 2023 and ALS One Symposium
(Businesswire)
- "As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in Amyotrophic Lateral Sclerosis (ALS), at Neuroscience 2023 in Washington, D.C. on November 15 and the ALS One Symposium on November 17....In vivo proof-of-concept studies have showcased the effectiveness of SOL-257 gene therapy in alleviating TDP-43-related toxicity in both the TDP-43-based mouse model and the C9orf72-based ALS mouse model. The compelling results from a range of behavioral tests provide strong support for the ongoing preclinical development of SOL-257 as a potential ALS therapeutic."
Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders
November 03, 2023
Preclinical proof of concept of SOL-257, a gene therapy targeting misfolded TDP-43 in ALS
(Neuroscience 2023)
- "This in vivo proof of concept study demonstrated that SOL-257 gene therapy can effectively prevent TDP-43-related toxicity in the rNLS mouse model of ALS. These results provide strong support for the ongoing preclinical development of SOL-257 for the treatment of ALS. Additionally, this versatile gene therapy platform, capable of expressing engineered co-chaperones with different target specificities, holds promising potential for the treatment of protein misfolding diseases in general."
Gene therapy • Preclinical • CNS Disorders • Proteinopathy • NEFH • TARDBP
October 03, 2023
SOLA Biosciences Shares Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS at 22nd Annual NEALS Meeting
(Businesswire)
- "SOLA Biosciences...will present its encouraging preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in ALS, at the 22nd Annual Northeast ALS Consortium (NEALS) Meeting held in Florida on October 5....The in vivo proof-of-concept studies demonstrated the effectiveness of SOL-257 gene therapy in mitigating TDP-43-related toxicity in both the TDP-43-based mouse model and the C9orf72-based ALS mouse model. The compelling results from various behavioral tests provide strong support for the continued preclinical development of SOL-257 as a potential ALS therapeutic."
Preclinical
1 to 4
Of
4
Go to page
1